Industry News

Cellular Biomedicine Group Inc., a clinical-stage biomedicine firm engaged in the development of immunotherapies for cancer and effective stem cell therapies for degenerative diseases, today reported financial results and business highlights for the second quarter and six months ended June 30, 2016.. “In the first half of 2016, we made several significant advancements..."/>
Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
Moberg Pharma AB reported on Tuesday that its net profit after tax was SEK28.0m, or EPS of SEK1.96, for the second quarter of 2016, from April 2016 to June 2016.. This was in comparison with net profit after tax of SEK5.5m, or EPS of SEK0.38, in Q2 of 2015.. Revenues for the second quarter were SEK71.3m, as compared with SEK92.2m in Q2 2015.."/>
Moberg Pharma posts net profit of SEK28.0m in Q2 2016
Moberg Pharma AB reported on Tuesday that its net profit after tax was SEK28.0m, or EPS of SEK1.96, for the second quarter of 2016, from April 2016 to June 2016.. This was in comparison with net profit after tax of SEK5.5m, or EPS of SEK0.38, in Q2 of 2015.. Revenues for the second quarter were SEK71.3m, as compared with SEK92.2m in Q2 2015.."/>
Moberg Pharma posts net profit of SEK28.0m in Q2 2016
Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at 10:55am EDT at the Le Parker Meridien Hotel in New York City, NY.. The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations..."/>
Achillion to Present at the 2016 Wedbush PacGrow Healthcare Conference
BioDelivery Sciences International, Inc. today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones. BDSI's total net revenue for the three-months ended June 30, 2016, was $5.0 million, an increase of 65% over the first quarter of 2016 and an increase of 189% over last year's corresponding quarter. BUNAVAIL buccal film net revenue for the three..."/>
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results
Haemonetics Corporation reported on Tuesday the acquisition of 60,000 shares of its common stock at an average price per share of USD35.00 by its president and CEO Christopher Simon via open market purchases during the last three business days. In conjunction, the company will match up to USD2m of Simon's share purchases with an equal number of relative performance-based share units under the terms of the compensation agreement. The company said the..."/>
Haemonetics' CEO concludes purchase of 60,000 common stock in the open market
Sunshine Heart, Inc. announced today its financial results for the second quarter ended June 30, 2016. The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’ s clinical and product development strategy and its recent acquisition of the Aquadex FlexFlow ® product line. To access the live webcast, please visit the Investors page of the Sunshine Heart website at..."/>
Sunshine Heart Announces Second Quarter 2016 Financial Results and Provides Company Update
HCA Holdings said on Monday that it plans to offer USD1.0bn aggregate principal amount of senior secured notes. This offering of senior notes has been initiated by the company's wholly owned subsidiary, HCA Inc, which is subject to market and other considerations. The company stated that the actual terms of the notes, including interest rate and principal amount, will depend on market conditions at the time of pricing."/>
HCA to issue USD1.0bn senior secured notes in planned public offering
Cardinal Health on Monday declared a quarterly dividend of USD0.4489 per share of the company's stock. This quarterly dividend is due on 15 October to shareholders of record at the close of business as of 3 October. Cardinal Health is an integrated healthcare services and products company that provides customised solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide."/>
Cardinal Health's board to pay USD0.4489 per share dividend
NeuroVive Pharmaceutical AB, the mitochondrial medicine company, today announces that research results from the NVP015 program investigating a novel pharmacological strategy for the treatment of mitochondrial disease has been published in Nature Communications, the third highest ranked multidisciplinary scientific journal in the world. The research was performed in collaboration between NeuroVive and Lund University, Newcastle University, Selcia/Mitopharm Ltd..."/>
Neurovive Pharmaceutical: NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications
Perrigo Company reported on Monday the completion of the sale of its US Vitamins, Minerals& Supplements business. Under the terms of the agreement, the company sold its US Vitamins, Minerals& Supplements business to International Vitamin Corporation. Financial details of the agreement have not been disclosed by the companies."/>
Perrigo disposes Vitamins, Minerals & Supplements business in the US for undisclosed fee
Evoke Pharma announced on Monday the repayment all of the outstanding amounts of debt of USD4.5m under its loan and security agreement with Square 1 Bank, a division of Pacific Western Bank. Following the repayment of this debt, the company will eliminate interest expenses from the facility of approximately USD250, 000 a year. According to Dave Gonyer, the company's president and CEO, the repayment coupled with its recent equity financings, provide the..."/>
Evoke Pharma repays USD4.5m under its loan and security deal
Arbutus Biopharma Corporation reported on Monday that it has been granted a new patent under its proprietary lipid nanoparticle delivery technology portfolio in the US. This new patent, which has been assigned US 9,404,127, bolsters the company's intellectual property for its proprietary lipid nanoparticle delivery technology as well as encompass populations of lipid particles effective for delivering nucleic acid payloads, including..."/>
Arbutus awarded new US patent for LNP delivery technology for nucleic acids including mRNA
BioMarin Pharmaceutical reported on Monday that it has issued 7,500,000 shares of its common stock in an underwritten public offering. The company added that it has provided the underwriters with a 30- day option to purchase an additional 750,000 shares of common stock. Net proceeds from the offering may be used by the company for general corporate purposes, clinical trials of its product candidates, expansion of its manufacturing capacity,..."/>
BioMarin reports public offering 7.5m common stock
HCA Holdings Inc announced on Monday that its wholly owned subsidiary, HCA Inc, proposes to offer, subject to market and other considerations, USD1.0bn aggregate principal amount of senior secured notes. According to the company, the actual terms of the notes, including interest rate and principal amount, will depend on market conditions at the time of pricing. Reportedly, HCA Inc intends to use the net proceeds of this offering to refinance a portion of its term loan B-4 facility..."/>
HCA’s subsidiary proposes USD1.0bn public offering of senior secured notes
Hutchison China Meditech Limited. London: Tuesday, August 9, 2016: Hutchison China MediTech Limited has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US $1.00 each in Chi-Med at a price of GBP19.00 and GBP18.99 per share respectively on August 4, 2016.. Following the above transaction, the combined holding of Mr Nash and his spouse is 39,596 Ordinary..."/>
Hutchison China Meditech Limited: Director's Share Dealing
AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK 1/ 2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd- line treatment in patients with KRAS mutation-positive locally-advanced or metastatic non-small cell lung cancer. Array BioPharma was informed of these results on Monday, August 8, 2016.. The results showed that the trial did not meet its primary endpoint of progression-free..."/>
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Wockhardt Ltd plunged almost 10% on Monday after the US Food and Drug Administration on the weekend banned imports from the drug maker's plant in Ankleshwar, Gujarat. In its order on Friday, the FDA cited non-compliance with current good manufacturing practices in slapping the ban on the active pharmaceutical ingredients plant. Wockhardt shares ended trading down 9.88% at Rs.915.30 on Monday after having fallen as much as 14% in early trading."/>
Wockhardt shares dive 9.8% on US import ban [Mint, New Delhi]
Citigroup Inc. and Credit Suisse Group AG to find a buyer at a valuation of $1.5 billion, said one of the people, both of whom requested anonymity. "The combined stake may fetch a better valuation as the..."/>
Mu Sigma CEO Ambiga Subramanian, General Atlantic in bid to sell stake [Mint, New Delhi]
Acadia Pharmaceuticals intends to sell $200 million in stock, the San Diego biopharmaceutical company said Monday. The company will use the net proceeds of about $187.5 million to fund commercialization and further testing of its drug Nuplazid, according to the prospectus. Nuplazid sales recently began for Parkinson's disease psychosis."/>
Acadia files for $200 million stock offering [The San Diego Union-Tribune]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary666 Articles
Information Technology596 Articles
Financials520 Articles
Industrials371 Articles
Health Care355 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.